GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial
Psychopharmacology Bulletin · 04.06.2026 · 56 (3) · 8-21
DOI: 10.64719/pb.18507 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 04.06.2026. Verfasst von Michael E Thase und 5 weiteren Autor:innen. Beteiligte Einrichtung: Thase, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J Crescenz Veterans…. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Antidepressive Agents, Major Depressive Disorder, Organophosphates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Depression
Abstract (Originalsprache)
Background
Approximately 30% of patients treated for major depressive disorder develop treatment-resistant depression (TRD). The STAR*D study demonstrated remission rates decline progressively with each antidepressant failure (37%, 31%, 14%, and 13%, respectively). A single-day individualized dosing regimen of GH001 (synthetic mebufotenin for inhalation) produced rapid, large improvements in depressive symptoms versus placebo in patients with TRD in a Phase 2b trial (least-squares mean difference, −15.5; effect size, −2.0; 57.5% remission at Day 8 versus 0% placebo). The current post hoc analysis examines whether GH001 efficacy varies by number of prior lifetime antidepressant treatment failures.
Methods
This analysis included all 40 patients who received GH001 in the double-blind part of a Phase 2b trial. Spearman rank correlations between number of prior lifetime antidepressant failures and change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) scores were calculated at Day 8 and among 6-month open-label extension completers. Remission rates (MADRS ⩽10) were examined by subgroup (2, 3, 4, or ⩾5 prior lifetime failures).
Results
No meaningful correlation was observed between prior lifetime treatment failures and MADRS improvement at Day 8 (r = −0.13; P = 0.44) or 6-month OLE completers (r = −0.10; P = 0.60). Remission rates at Day 8 likewise were similar across subgroups (range, 53.9%–63.6%) and were maintained at end of treatment visit/Month 6 (range, 61.5%–85.7%). Secondary endpoints were not associated with treatment history.
Conclusions
The efficacy of GH001 in patients with TRD appears largely independent of number of prior lifetime antidepressant treatments, and further research in patients with extensive treatment histories will be conducted in subsequent development stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thase, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.
- Brennan, GH Research, Dublin, Ireland.
- MacIsaac, GH Research, Dublin, Ireland.
- Pani, Miami University, Miami, USA; University of Modena and Reggio Emilia, Modena, Italy.
- Valcheva, GH Research, Dublin, Ireland.
- Cubała, Department of Psychiatry, Faculty of Medicine, Medical University of Gdan´sk, Gdan´sk, Poland.
Zitieren
APA
Thase, M. E., Brennan, B., MacIsaac, R., Pani, L., Valcheva, V., & Cubała, W. J. (2026). GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial. Psychopharmacology Bulletin, 56(3), 8-21. https://doi.org/10.64719/pb.18507
Vancouver
Thase ME, Brennan B, MacIsaac R, Pani L, Valcheva V, Cubała WJ. GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial. Psychopharmacology Bulletin. 2026;56(3):8-21. doi:10.64719/pb.18507
BibTeX
@article{Thase2026,
author = {Thase, Michael E and Brennan, Brian and MacIsaac, Rachael and Pani, Luca and Valcheva, Velichka and Cubała, Wiesław J},
title = {GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial},
journal = {Psychopharmacology Bulletin},
year = {2026},
volume = {56},
number = {3},
pages = {8--21},
doi = {10.64719/pb.18507}
}
EUVIMED